GTx-758 is an oral luteinizing hormone (LH) inhibitor developed for the treatment of advanced prostate cancer.

Preclinical in vitro and in vivo data suggest GTx-758 rapidly suppresses secretion of LH, by feedback inhibition on the pituitary gland, thereby inhibiting production of androgens by the testes. In preclinical models, GTx-758 has demonstrated its potential to achieve medical castration by reducing testosterone, considered as primary growth factor of prostate cancer.

According to researchers, common side effects caused by current androgen deprivation therapies (ADT) for prostate cancer, such as hot flashes, bone los, adverse lipid changes, are excluded by GTx-758 use.

We believe GTx-758, with an oral formulation and the potential to treat prostate cancer through suppression of testosterone without also causing bone loss and hot flashes could become best in class androgen deprivation therapy.

| 15.07.2009 |

Ipsen and GTx partnership

Ipsen (Paris:IPN) and GTx, Inc. (Nasdaq: GTXI) recently announced the expansion of their partnership for the development and commercialization.

This new agreement with GTx gives Ipsen expanded market reach and rights for toremifene, in what they view as significant unmet medical needs for patients suffering from prostate cancer. It will strengthen Ipsen’s franchise in hormone-dependent cancers and broaden our drug range in the oncology area

Under the terms of the amended collaboration agreement, GTx has granted Ipsen (among others) the first right of negotiation under certain conditions for rights to GTx-758, currently in Phase II clinical trial for the first-line treatment of men with advanced prostate cancer, in Ipsen’s licensed toremifene territories.

| 23.03.2010 |

GTx-758 causes medical castration

Higher doses of GTx-758 were shown in an early-stage trial to induce temporary medical castration in healthy volunteers, the GTx Inc said on Tuesday, September the 14th.

GTx aims to begin two mid-stage trials of the drug early next year. One is to be in patients diagnosed with advanced prostate cancer and another in those who have failed to respond to injectable drugs, like Lupron, used to treat the cancer by reducing the amount of testosterone made by the body. Most types of prostate cancer need the male hormone testosterone to grow and spread.

The trial with 60 healthy volunteers found that medical castration was achieved in subjects given either 1,000 mg or 1,500 mg of the drug, called GTx-758, but not a lower dose of 600 mg.

The company said the percentage of treatment-compliant subjects receiving 1,500 mg who achieved medical castration was comparable to rates seen with treatments like Lupron. Castration was seen in these subjects within three weeks.

As a selective estrogen receptor alpha agonist, GTx-758 has the potential to achieve medical castration by inhibition of the pituitary and hypothalamus without bone loss or hot flashes, the company says.

GTx said it expects to report full results from the trial at upcoming medical meetings.

| 15.09.2010 |

GTx presents preclinical studies of GTx-758 for treatment of cancer

Results of preclinical studies evaluating GTx-758 were presented this past weekend in Atlanta at the annual meeting of the Society of Basic Urologic Research (SBUR).

GTx, Inc. (Nasdaq: GTXI) presented results of three preclinical GTx-758 studies at the SBUR: